Dr Gabbay:I think it’s really important that we advise our patients on strategies that can mitigate that loss of lean muscle mass. One is strength training can be helpful, and 2, ensuring appropriate protein intake. ...
GLP-1具有葡萄糖浓度依赖性降糖作用 作为一种肠源性激素,GLP-1是在营养物质特别是碳水化合物的刺激下才释放入血的,其促胰岛素分泌作用呈葡萄糖浓度依赖性,Nauck等[6]对10例血糖控制不佳的2型糖尿病患者进行了研究,并在空腹状态下分别给予患者GLP-1或安慰剂,结果显示,患者在输注GLP-1后,其胰岛素和C肽水平显著...
Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine. 2020 Jun;68(3):518-25. Lee J, Kim R, Kim MH, et al. Weight ...
Because native GLP-1 has a very short half-life in vivo protease-resistant but potentially immunogenic GLP-1-analogs and mimetics (such as exenatide) with extended half-life are being used for evaluation of efficacy against Type 1 diabetes. However, 38% of type 2 diabetic patients that used ...
tolerability of exenatide monotherapy over 24 weeks in antidiabeticdrug‑naivepatientswithtype 2 diabetes: a 八、小结与展望 randomized, double‑blind, placebo‑controlled, GLP‐1RA不仅降糖疗效确切,还具有许多降糖 parallel‑group study[J]. Clin Ther, 2008, 30(8): 1448‑1460. DOI: 10.1016/...
[6] Toft-Nielsen, M B et al. “Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.” The Journal of clinical endocrinology and metabolism vol. 86,8 (2001): 3717-23. doi:10.1210/jcem.86.8.7750 ...
了解GLP-1影响体重的相关机制。 自胰高糖素样肽-1(GLP-1)被发现以来,已然成为一种“多面手”激素——其接二连三的代谢功能被人们发现,远远超出了作为肠促胰素的经典定义。GLP-1众多有益的作用使其受体激动剂逐渐成为更多新兴的治疗领域如脂肪肝、肥胖和神经退行性疾病等的冉冉之“星”药物,而GLP-1的减重作用...
[6] Vilsboll, T., Agerso, H., Krarup, T., Holst, J.J. 2003. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224. [7] Bettge, K., Kahle, M., Abd El Aziz, M.S., Meier, J.J., Na...
2.Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001 Aug;86(8):3717-23. 3.GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PR...
About 50,000 Danish diabetic patients are treated with GLP-1-based medicine. GLP-1 is a hormone that reduces the blood sugar and inhibits the appetite, and it is a frequent treatment for type 2 diabetes and obesity. A known side effect of this particular treatment is that it increases pati...